Bio-Rad has sponsored the development of
this site to advance the productivity of the American Biotechnology sector and the fine people who
work in it across the country. We invite readers to contribute content:
posters, tools, research and presentations, articles white papers, multimedia, music
downloads and entertainment, conference announcements, videos. Please contact email@example.com more information.
Download the Protein Blotting Guide
Download the Stem Cell Guide for Life Science Researchers
:: Posted by American Biotechnologist on 10-08-2013
Large-scale cancer genomics studies have established an extensive and unprecedented catalog of somatic mutations in multiple cancer types. This landscape was determined using mostly highly cellular, untreated primary tumors and is mostly static with limited implications to understand cancer progression and drug response in the clinic.
Tumors are composed of multiple cell types: stromal, immune or malignant cells. Malignant cells can also show sub-clonal heterogeneity, where different clones carry various somatic mutations and show variable oncogenic potential or drug sensitivity. Finally this sub-clonal population can change during the progression of cancer or as a consequence of the treatment. Additional genomic heterogeneity arises through the characteristic signatures of the various mutational processes that drive genome disruption during tumorigenesis, which highly powered technologies are beginning to resolve.
In a webinar presented by Bio-Rad and Genome Biology, Elaine Mardis (Washington University in St Louis), a world leader in the field of cancer genomics, and Olivier Harismendy (University of California San Diego), who is developing clinical assays in which next-generation sequencing is combined with digital PCR, discuss the latest developments and outstanding questions that relate to viewing cancer genomes at high resolution. The webinar will be open for audience discussion.
► Register for the webinar
New York (U.S.A. – New York) Wednesday, October 23, 2013 at 10:00:00 AM EDT
San Francisco (U.S.A. – California) Wednesday, October 23, 2013 at 7:00:00 AM PTD
:: Posted by American Biotechnologist on 05-23-2013
This video first aired three and a half years ago. It was very accurate in 2009 and I believe that it is still relevant today. How much has our approach to cancer research changed since this video was recorded?
:: Posted by American Biotechnologist on 09-05-2012
In the face of mounting evidence that cancer cells communicate, cooperate and even engage in collective decision-making, biophysicists and cancer researchers at Rice University, Tel Aviv University and Johns Hopkins University are suggesting a new strategy for outsmarting cancer through its own social intelligence.
Article co-author Eshel Ben-Jacob, a senior investigator at Rice’s Center for Theoretical Biological Physics (CTBP), said, “Cancer is a sophisticated enemy. There’s growing evidence that cancer cells use advanced communications to work together to enslave normal cells, create metastases, resist drugs and decoy the body’s immune system.”
“It’s time to declare a cyber war on cancer,” said Ben-Jacob, who, along with Coffey, is speaking today at a workshop titled “Failures in Clinical Treatment of Cancer” at Princeton University.
:: Posted by American Biotechnologist on 07-07-2010
This video was put together by the American Association for Cancer Research in advance of their 2010 meeting which was held in Washington, D.C. this past April. The video is very similar in style and format to the “Did You Know” video that we shared with you a few months ago and has been making its way across the internet for several years.
The video inspires an appreciation for the epidemic proportion of cancer, how far cancer research has advanced and how much further there is to go. Some of the facts that I found truly incredible include:
There are 17,590 P53 citations and 0 FDA approved P53 drugs
There are 10,421 RAS citations and 0 FDA approved RASdrugs
The average age for receiving a first grant has gone from 34 in 1980 to 42 today
There are over 100 cancer genomes that have been sequenced so far, up from only 1 cancer genome sequenced in 1998
One question to ponder is why the lack of FDA approved drugs when so many papers have been published on P53 and RAS? Are we missing something? Are we taking the wrong approach to “solving” such a complex, multi-factorial disease?